Abbott Laboratories experienced key developments including an increase in its
quarterly dividend by 6.8%. Major stakeholders like Ameriprise Financial Inc., Curi Capital LLC, and Elevatus Wealth Management have recently increased their holdings, revealing continued investor confidence. A significant acquisition is underway as Abbott is set to take over
Exact Sciences - a leader in cancer screening and precision oncology diagnostics. Despite a pullback last week, year-long returns for the company are promising at 8.3%.
Abbott's growth strategy is also reflected in the expansion of the board and a focus on strengthening its product portfolio, underlined by CGM expansion and credible protein-glucose data release. However, the company is facing legal challenges related to infant formula lawsuits seeking congressional intervention. Despite some shares being sold by institutional investors and insider sales, numerous
buy ratings from financial firms such as Citi and UBS along with steady device growth providing substantial revenue lend Abbott optimistic prospects.
Abbott Laboratories ABT News Analytics from Wed, 16 Apr 2025 07:00:00 GMT to Sat, 13 Dec 2025 13:29:21 GMT -
Rating 7
- Innovation 5
- Information 8
- Rumor -2
